BACKGROUND: Despite the fact that new drugs have emerged from clinical research in @entity5 during the last decade, the prognosis of @entity1 with @entity1442 remains poor with a median survival of 12 to 14 months. We designed a feasibility study of @entity136 and @entity901 (GO) in @entity1 with advanced @entity5 . @entity1 AND METHODS: Twenty @entity1 received bimonthly cycles of @entity136 1500 mg/m2 and @entity901 85 mg/m2. The cycles were given at 2-week intervals without @entity1261 support. Thirteen @entity1 were treated with the GO combination as first-line chemotherapy because of a poor performance status or a @entity1011 clearance < 1 ml/s. RESULTS: The median number of cycles of GO was 5 (1-7). The median number of days between cycles was 14 throughout the treatment. Seven (8%) out of 87 cycles had to be delayed because of @entity1398 or @entity1395 . A 25% dose reduction in the doses of cytotoxic drugs was necessary in 2 @entity1 . Chemotherapy was stopped before the sixth cycle because of an early death related to a @entity583 in 1 @entity1 , a grade 3 @entity16 in 1 @entity1 and a progressive disease in 9 @entity1 . CONCLUSION: Using these doses and schedules, the GO regimen appears a safe therapy for @entity1 with advanced @entity5 . Phase II studies are required to assess the possible role of this combination in advanced @entity5 .

XXXX and @entity901 in advanced transitional cell carcinoma of the urothelium: a pilot study.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS'] @entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin'] @entity1261 :: ('1440', 'Gene') :: ['G-CSF'] @entity5 :: ('MESH:D009369', 'Disease') :: ['urothelial cancer'] @entity16 :: ('MESH:D009422', 'Disease') :: ['neuropathy'] @entity1395 :: ('MESH:D001247', 'Disease') :: ['asthenia'] @entity1442 :: ('MESH:D020178', 'Disease') :: ['advanced disease'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine']
@entity136 :: (MESH:C056507,Chemical) :: ['Gemcitabine']
